IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Studies show that administration of interferon (IFN)-alpha causes a significant increase in depressive symptoms. The enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan (TRP) into kynurenine (KYN) and which is stimulated by proinflammatory cytokines, may be implicated in the development of IFN-alpha-induced depressive symptoms, first by decreasing the TRP availability to the brain and second by the induction of the KYN pathway resulting in the production of neurotoxic metabolites. Sixteen patients with chronic hepatitis C, free of psychiatric disorders and eligible for IFN-alpha treatment, were recruited. Depressive symptoms were measured using the Montgomery Asberg Depression Rating Scale (MADRS). Measurements of TRP, amino acids competing with TRP for entrance through the blood-brain barrier, KYN and kynurenic acid (KA), a neuroprotective metabolite, were performed using high-performance liquid chromatography. All assessments were carried out at baseline and 1, 2, 4, 8, 12 and 24 weeks after treatment was initiated. The MADRS score significantly increased during IFN-alpha treatment as did the KYN/TRP ratio, reflecting IDO activity, and the KYN/KA ratio, reflecting the neurotoxic challenge. The TRP/CAA (competing amino acids) ratio, reflecting TRP availability to the brain, did not significantly change during treatment. Total MADRS score was significantly associated over time with the KYN/KA ratio, but not with the TRP/CAA ratio. Although no support was found that IDO decreases TRP availability to the brain, this study does support a role for IDO activity in the pathophysiology of IFN-alpha-induced depressive symptoms, through its induction of neurotoxic KYN metabolites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cytokine-induced activation of the enzyme, indolamine 2,3 dioxygenase (IDO), which metabolizes tryptophan to kynurenine and quinolinic acid, is believed to contribute to reduced availability of serotonin.16,23,24”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [24]
In the citing paper
“Following IDO activation, both the reduced peripheral availability of tryptophan (putatively leading to reduced serotonin synthesis in the brain) and the production of neurotoxic tryptophan metabolites are considered essential steps in the pathophysiological processes.”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“which converts tryptophan into kynurenine (KYN), a precursor of 3-hydroxykynurenine, a neurotoxic metabolite, and kynurenic acid, a neuroprotective metabolite”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“kynurenic acid is an N-methyl d-aspartate (NMDA) receptor antagonist, and is generally considered neuroprotective”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Research works printed but not linked: 2
- Maes M, Meltzer H . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, (eds) Psychopharmacology. Raven Press: New York, 1995 pp 933–944.
- Stockmeier CA, Mahajan G, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Neuronal and glial density is increased and neuronal soma size is decreased in the hippocampus in major depressive disorder (MDD). Biol Psychiatry 2003; 53S: 198.
Cited by
Items 301–400 of 445
Effects of Xiao Yao San on interferon-α-induced depression in mice
Wang, M., Huang, W., Gao, T., Zhao, X., & Lv, Z. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.001 · Cited by 17
Interferon-induced depressive illness in hep C patients responds to SSRI antidepressant treatments
Gupta, R. K., Kumar, R., & Bassett, M. L. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.3.355 · Cited by 16
Lowe, X. R., Marchetti, F., Lu, X., & Wyrobek, A. J. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2008.12.012 · Cited by 15
“treatment of patients with chronic hepatitis or cancer can cause neuropsychiatric complications (Kraus et al., 2005; Wichers et al., 2005; Capuron et al., 2007).”
BackgroundNew role of sertraline against Toxoplasma gondii ‐induced depression‐like behaviours in mice
Lan, H., Lu, Y., Zhao, X., Jin, G., Lu, J., Jin, C. H., Ma, J., Jin, X., Xu, X. M., & Piao, L. X. (2021) · Parasite Immunology · doi:10.1111/pim.12893 · Cited by 14
Hao, K., Qu, Q., Hao, H., Wang, G., Chen, Y., Liang, Y. L., & Xie, L. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054981 · Cited by 15
“In fact, heightened glutamate activity might play an important role in major depression [11,12].”
BackgroundAlthough serotonin is not a major player in depression, its precursor is
Almulla, A. F., & Maes, M. H. J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02092-1 · Cited by 15
Self-citationStudy on the comorbid mechanisms of sarcopenia and late-life depression
Wu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115538 · Cited by 12
“…IL-1 β and TNF-α , also increase the activity of indoleamine 2,3-dioxyge-nase (IDO), leading to reduced conversion of tryptophan into 5-HT and promoting its metabolism into neurotoxic tryptophan catabolites (TRYCATs) such as kynurenine, both of which have been associated with depression[175].”
Badamasi, I. M., Maulidiani, M., Lye, M. S., Ibrahim, N., Shaari, K., & Stanslas, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210611095320 · Cited by 11
“The activity of the KYN pathway,which was promoted by pro-inflammatory cytokines that activate the indoleamine 2,3-dioxygenase (IDO) responsible for catalysing the metabolism of tryptophan into KYN as well as increasing activation of the KYN pathway, play a substantial role in the reductions of 5-HT synthesis levels i…”
Aarsland, T. I. M., Instanes, J. T., Posserud, M.-B. R., Ulvik, A., Keßler, U., & Haavik, J. (2022) · Pharmaceuticals · doi:10.3390/ph15111439 · Cited by 14
“Pathway activation and balance have been suggested to be related, as inflammation induced activation of the pathway potentially causes a larger increase in HK and QA relative to the side-branch metabolite KA [2,77,78].”
BackgroundPanov, G., Dyulgerova, S., Panova, P., & Stefanova, S. (2024) · Biomedicines · doi:10.3390/biomedicines12112646 · Cited by 14
Metabolomics in Schizophrenia and Major Depressive Disorder
Petrovchich, I., Sosinsky, A. Z., Konde, A. S., Archibald, A. R., Henderson, D. C., Maletić‐Savatić, M., & Milanovic, S. M. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1400-8 · Cited by 12
Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder
Duarte-Silva, E. P., Maes, M. H. J., Macêdo, D. S., Savino, W., & Peixoto, C. A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01105-9 · Cited by 13
Self-citationZhou, J., Zhou, J. L., Sun, Z., Feng, L., Feng, Y., Xiao, L., Chen, X., & Yang, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.069 · Cited by 14
Yoshida, J., Shigemura, A., Ogino, Y., Denbow, D. M., & Furuse, M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.005 · Cited by 12
“QUIN has a neurotoxic effect while KYNA has a neuroprotective effect (Myint and Kim, 2003; Wichers et al., 2005).”
BackgroundKYNURENINES IN PATHOGENESIS OF ENDOGENOUS PSYCHIATRIC DISORDERS
Shilov, Y., & Mv, B. (2013) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v68i1.535 · Cited by 17
Animal Models for Depression Associated with HIV-1 Infection
Barreto, I. C. G., Viegas, P. D. B., Ziff, E. B., & Konkiewitz, E. C. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9518-9 · Cited by 14
“Winchers and colleagues showed that patients receiving IFN-α therapy have an increase in the serum KYN/KYNA ratio that was significantly associated with the severity of depression (Wichers et al. 2005).”
ResultSackey, B., Shults, J. G., Moore, T. A., Rogers, R., Mehvar, M., & King, J. G. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.05.116 · Cited by 11
“model of depression, which implicates increased cytokine activity as a cause of depressive morbidity.(24) Direct-acting”
BackgroundMethodResultChanges of Altruistic Behavior and Kynurenine Pathway in Late-Life Depression
Wu, Y., Mai, N., Weng, X., Liang, J., & Ning, Y. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00338 · Cited by 12
“The shunt of TRP from 5-HT formation to KYN formation is a major etiological factor of depression (13, 14).”
BackgroundKhoshnevisan, K., Chehrehgosha, M., Conant, M., Meftah, A. M., Baharifar, H., Ejtahed, H., Angoorani, P., Gholami, M., Sharifi, F., Maleki, H., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15533 · Cited by 12
“The presence of inflammatory factors that occur as a result of systemic or local stimulation of the immune system leads to the activation of IDO that may be contributed to stimulate the cerebral Kyn pathway in neurological disorders (Maes & Rief, 2012; Wichers et al., 2005).”
BackgroundDepression and pegylated interferon-based hepatitis C treatment
Papafragkakis, H., Rao, M. S., Moehlen, M., Dhillon, S., & Martin, P. (2012) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s28901 · Cited by 12
Vignau, J., Costisella, O., Canva, V., Imbenotte, M., Duhamel, A., & Lhermitte, M. (2008) · L Encéphale · doi:10.1016/j.encep.2007.09.007 · Cited by 11
Guo, H., Chen, H., Yang, Y., Xie, D., Dang, Y., Xiang, M., & Yu, Y. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124392 · Cited by 10
Myint, K., Jacobs, K. R., Myint, A.-M., Lam, S. K., Lim, Y. A. L., Boey, C. C. M., Hoe, S.-Z., & Guillemin, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702301 · Cited by 11
“This may be due to its immunosuppressive effect as well as regenerative effect as IL-6dependent mucosal protection was demonstrated in enteric bacterial pathogen (61).”
BackgroundInfluentialTryptophan catabolism to serotonin and kynurenine in women undergoing in-vitro fertilization
Bódis, J., Sulyok, E., Koppán, M., Várnagy, Á., Prémusz, V., Gödöny, K., Rascher, W., & Rauh, M. (2020) · Physiological Research · doi:10.33549/physiolres.934435 · Cited by 11
Haverkamp, G. L. G., Loosman, W. L., Franssen, C. F. M., Kema, I. P., van Diepen, M., Dekker, F. W., Honig, A., & Siegert, C. E. H. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw212 · Cited by 11
Bruncsics, B., Hullám, G., Bolgár, B., Petschner, P., Millinghoffer, A., Gecse, K., Eszlári, N., Gonda, X., Jones, D. J., Burden, S. T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31495-x · Cited by 9
Liu, J., Si, J., & Zhao, W. (2024) · Experimental Aging Research · doi:10.1080/0361073x.2024.2377427 · Cited by 11
“…activity and KYN/KA ratio reflecting neurotoxic challenge in peripheral serum, and MADRS total score was significantly correlated with KYN/KA ratio (Wichers et al., 2005), and the increase in KYN and QUIN levels in cerebrospinal fluid and peripheral serum was significantly correlated with the…”
Kynurenines and Inflammation: A Remarkable Axis for Multiple Sclerosis Treatment
Carrillo‐Mora, P., Landa‐Solís, C., Valle‐García, D., Luna‐Angulo, A. B., Avilés‐Arnaut, H., Robles-Bañuelos, B., Sánchez‐Chapul, L., & Rangel‐López, E. (2024) · Pharmaceuticals · doi:10.3390/ph17080983 · Cited by 10
“…to hyper-or hypofunction of tryptophan catabolites [43], which are associated with some neurological disorders [43], such as depression, anxiety, peripheral inflammation, and chronic fatigue [44–48], that are considered key factors in MS progression and patient quality of life [49] (Figure 1).”
BackgroundBezemer, G., Gool, A. R. V., Fekkes, D., Vrolijk, J., Hansen, B. E., Janssen, H. L. A., & de Knegt, R. J. (2012) · Neuropsychobiology · doi:10.1159/000330585 · Cited by 11
Loftis, J. M., Morasco, B. J., Menasco, D., Fuchs, D., Strater, M., & Hauser, P. (2013) · The Open Infectious Diseases Journal · doi:10.2174/1874279301004010132 · Cited by 10
“Peripheral levels of serotonin and changes in tryptophan have been studied and were hypothesized to play a role in the etiology of the neuropsychiatric side effects associated with antiviral therapy, particularly depression [27, 28], but more recent reports including our own findings do not support consistent correlat…”
Relationship of Inflammation and Autoimmunity to Psychiatric Sequelae in Lyme Disease
Bransfield, R. C. (2012) · Psychiatric Annals · doi:10.3928/00485713-20120906-07 · Cited by 9
Haverkamp, G. L. G., Loosman, W. L., Schouten, R. W., Franssen, C. F. M., Kema, I. P., van Diepen, M., Dekker, F. W., Siegert, C. E. H., & Honig, A. (2017) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2017.10.003 · Cited by 10
Wigner, P., Synowiec, E., Jóźwiak, P., Czarny, P. L., Bijak, M., Białek, K. I., Szemraj, J., Gruca, P., Papp, M., & Śliwiński, T. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01563-2 · Cited by 9
Oberst, P., Xu, N., Munguba, H., Zhang, C., Zhong, A., Zhou, T., Liston, C. M., Levitz, J., & Studer, L. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.08.011 · Cited by 10
Baranyi, A., Enko, D., Meinitzer, A., von Lewinski, D., Rothenhäusler, H., Harpf, L., Traninger, H., Obermayer-Pietsch, B. M., Harb, B. M., Schweinzer, M., et al. (2022) · Antioxidants · doi:10.3390/antiox11112083 · Cited by 11
Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders
de Miranda, A. S., Toscano, E. C. D. B., O’Connor, J. C., & Teixeira, A. L. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2366872 · Cited by 10
Mo, G., Wang, Z. X., Chen, X., & Jiang, Q. (2020) · BioPsychoSocial Medicine · doi:10.1186/s13030-020-00196-6 · Cited by 18
Cheng, S., Li, J., Chen, D. T.-L., Chien, Y.-C., Chang, J. P., Huang, S., Gałecki, P., & Su, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030192 · Cited by 9
“However, the induction of neurotoxic KYN metabolites during inflammation is also a possibility [35].”
BackgroundInflammation in Suicidality: Implications for Novel Treatment Options
Janelidze, S., & Brundin, L. (2013) · Modern trends in psychiatry · doi:10.1159/000346085 · Cited by 8
Krause, D., Kirnich, V. B., Stapf, T. M., Hennings, A., Riemer, S., Riedel, M. J., Schmidmaier, R., Gil, F. P., Rief, W., & Schwarz, M. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.1.34 · Cited by 9
Do Thyroid Abnormalities Detected in Patients Treated for HCV-Related Chronic Hepatitis Persist?
Tarantino, G., Gagliardi, G., & Conca, P. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100228 · Cited by 8
Metabolomics: A Global Biochemical Approach to the Discovery of Biomarkers for Psychiatric Disorders
Kaddurah‐Daouk, R., Soares, J. C., & Quinones, M. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_6 · Cited by 11
Almulla, A. F., Thipakorn, Y., Vasupanrajit, A., Algon, A. A. A., Tunvirachaisakul, C., Aljanabi, A. A. H., Oxenkrug, G. F., Al‐Hakeim, H. K., & Maes, M. H. J. (2022) · medRxiv · doi:10.1101/2022.06.13.22276359 · Cited by 8
Self-citationThe major biogenic amine metabolites in mood disorders
Yang, H. J., Yuan, M., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1460631 · Cited by 8
Costa, A., & Lucarini, E. (2024) · Nutritional Neuroscience · doi:10.1080/1028415x.2024.2365021 · Cited by 10
Bassiony, M. M., Yousef, A. M., Youssef, U. M., El-deen, G. M. S., Abdelghani, M., Al-Gohari, H., Fouad, E., & El-Shafaey, M. (2015) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217415605029 · Cited by 8
“In addition, cytokines can reduce serotonin levels by decreasing the availability of tryptophan and altering the ratio of kynurenine/ tryptophan.(29) In this study, 37.”
BackgroundEvaluation of the effect of soybean diet on interferon-α-induced depression in male mice.
Fashi, Y. A., Mesripour, A., & Hajhashemi, V. (2017) · PubMed Central · doi:10.22038/ajp.2017.20914.1793 · Cited by 17
“Soybean is a protein source comprised of tryptophan along with other amino acids (Banaszkiewicz, 2011), and for centuries, it has played a key role in the diet of many Asian countries (Yu et al., 2015).”
BackgroundVariation of Genes Encoding Tryptophan Catabolites Pathway Enzymes in Stroke
Wigner, P., Saluk, J., Synowiec, E., Miller, E. D., Śliwiński, T., Cichoń, N., & Bijak, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122133 · Cited by 9
“IDO may be activated by pro-inflammatory cytokines, whereas anti-inflammatory cytokines may act as inhibitors of the enzyme [16,17].”
BackgroundThe gut microbiome and psycho-cognitive traits
Vernice, N. A., Shah, N. B., Lam, E. H., Herd, P., Reiss, A. B., & Kasselman, L. J. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.08.014 · Cited by 8
Influence of gender on cytokine induced depression and treatment
Sarkar, S., Kemper, J., Sarkar, R., Brants, L., Friebe, A., Spengler, U., Schläpfer, T. E., Reimer, J., Buggisch, P., Ockenga, J., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.087 · Cited by 10
Pan, X., Liu, F., Song, Y., Wang, H., Wang, L., Qiu, H., Price, M., & Li, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.644540 · Cited by 7
Psychische Störungen bei somatischen Krankheiten
Kapfhammer, H. P. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_76 · Cited by 12
Advances of Molecular Clinical Pharmacology in Gastroenterology and Hepatology
PRANDOTA, J. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318195e34d · Cited by 7
“Interestingly, administration of IFN-a caused a significant increase in depressive symptoms, and it was found that IDO activity exerted an important role in the pathophysiology of these adverse effects, through its induction of neurotoxic kynurenine metabolites.(209) Progressive hepatitis C was also correlated with an…”
BackgroundExpression and Action of Cytokines in the Brain: Mechanisms and Pathophysiological Implications
Dantzer, R. (2007) · Elsevier eBooks · doi:10.1016/b978-012088576-3/50018-6 · Cited by 8
Gragnani, L., Lorini, S., Martini, L., Stasi, C., Visentini, M., Petraccia, L., Marello, N., Monti, M., Marri, S., Madia, F., et al. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05877-3 · Cited by 8
Savitz, J. B., Ford, B. N., Kuplicki, R., Khalsa, S. S., Teague, T. K., & Paulus, M. P. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06263-w · Cited by 7
Burden of psychiatric disease inversely correlates with Alzheimer's age at onset
Eijansantos, E., Allen, I. E., Deleon, J., Grasso, S. M., Rogers, N., Bogley, R., Paramo, A., Ehrenberg, A. J., Montembeault, M., Sturm, V. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70677 · Cited by 8
Mirzababaei, A., Mahmoodi, M. S., Abaj, F., Barkhidarian, B., Dehghani, A., Khalili, P., Roumi, Z., & Mirzaei, K. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1346074 · Cited by 7
Majdizadeh, G., Beytollahi, M., Djazayery, A., & Movahedi, A. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_59_23 · Cited by 6
“However, the clinical impact of the competitive effect of BCAAs is polemically discussed, [65] and the decrease in BCAAs in mental patients could lead to the alternative hypothesis that the mTor pathway might be dysregulated due to a lack of BCAAs, especially leucine, during depressive episodes.”
BackgroundVabo, I. L. C., Ferreira, L. E. V. V. D. C., & Fábio Heleno Lima, P. A. C. E. (2016) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032016000100005 · Cited by 6
“The BDI-II consists of 21 items and it was used in order to grade the depressive episode levels as minimum (0-13), mild (14-19), moderate (20-28) and severe (29-63)(4,7).”
BackgroundMethodFábregas, B. C., Vieira, É. L. M., Moura, A. S., Carmo, R. A., de Ávila, R. E., Abreu, M. N. S., Prossin, A. R., & Teixeira, A. L. (2016) · NeuroImmunoModulation · doi:10.1159/000444531 · Cited by 7
Managing the neuropsychiatric complications of hepatitis C treatment
Sockalingam, S., Shammi, C., & Stergiopoulos, V. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.10.27321 · Cited by 7
Cytokines, cancer and depression: connecting the dots.
Menzies, H., Chochinov, H. M., & BREITBART, W. S. (2005) · PubMed · Cited by 7
Interferon α bei Patienten mit chronischer Hepatitis C: Biopsychosoziale Auswirkungen
Baranyi, A., Meinitzer, A., Stepan, A., Matejka, J., Stauber, R. E., Kapfhammer, H. P., & Rothenhäusler, H. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3302-y · Cited by 5
Cytokine-Induced Sickness Behavior and Depression
Chang, Q., Szegedi, S. S., O’Connor, J. C., Dantzer, R., & Kelley, K. W. (2008) · Springer eBooks · doi:10.1007/978-0-387-84851-8_9 · Cited by 7
Pawełczyk, T., Pawełczyk, A. M., Białkowska, J., Jabłkowski, M., Strzelecki, D., Dworniak, D., & Rabe‐Jabłońska, J. (2008) · PubMed · Cited by 5
Long-term cellular and molecular signatures of pregnancy in the adult and ageing brainPreprint
Duarte‐Guterman, P., Richard, J. E., Lieblich, S. E., Eid, R., Lamers, Y., & Galea, L. A. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.24.529879 · Cited by 5
Bidzan-Wiącek, M., Tomczyk, M., Błażek, M., Mika, A., & Antosiewicz, J. (2024) · Nutrients · doi:10.3390/nu16213744 · Cited by 4
Polyák, H., Galla, Z., Rajda, C., Monostori, P. B., Klivènyi, P., & Vécsei, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030976 · Cited by 5
Kronfol, Z., Litman, H. J., Back‐Madruga, C., Bieliauskas, L. A., Lindsay, K. L., Lok, A. S.-F., & Fontana, R. J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.09.010 · Cited by 4
“It is also possible that depression is related to neurotoxicity of kynurenine and its metabolites which are stimulated by cytokines (Wichers et al., 2005), Alternatively, inflammatory cytokines, which are increased in major depression (Dowlati et al., 2009; Zorrilla et al., 2001), have been shown…”
BackgroundTackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics
Puccetti, M., Costantini, C., Ricci, M., & Giovagnoli, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040494 · Cited by 4
Biology of Depression and Cytokines in Cancer
Musselman, D. L., Miller, A. H., Royster, E. B., & McNutt, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470972533.ch3 · Cited by 6
The inhibition of phosphodiesterase type 5 as a novel target for antidepressant action
Liebenberg, N. (2009) · Cited by 5
Long-Term Neuropsychiatric Sequelae of COVID-19 in an Open Population: A Prospective Pilot Study
Rosas, Z. G., Martínez, H. C., Arroyo-Landín, M., Fragoso, G., Chávez‐Canales, M., Hernández, M., Rosetti, M., López-Alvarenga, J. C., Sciutto, E., & Cárdenas, G. (2025) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20240040 · Cited by 4
Mahdianipur, S., Maralani, M., Mohammadi, S., Khandoozi, S. R., Jafari, A., & Davoodi, H. (2024) · Cureus · doi:10.7759/cureus.70912 · Cited by 4
“Inflammation can induce depression in susceptible individuals by lowering plasma tryptophan levels and subsequently diminishing brain serotonin activity [3,4].”
BackgroundLos efectos conductuales modulados por las citocinas
Becerril‐Villanueva, E., Gutiérrez, M. E. H., Granados-Camacho, I., Alvarez, L., Pérez‐Tapia, S. M., & Romero, L. P. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 5
Oxenkrug, G. F., Wa, T., Zgrajka, W., Jv, W., Ruthazer, R., & D, P. S. M. (2014) · Cited by 3
Marazziti, D., Baroni, S., Picchetti, M., Piccinni, A., & Silvestri, S. (2016) · Cited by 3
Wigner, P., Synowiec, E., Jóźwiak, P., Czarny, P. L., Białek, K. I., Bijak, M., Szemraj, J., Gruca, P., Papp, M., & Śliwiński, T. (2020) · Genes · doi:10.3390/genes11091093 · Cited by 3
“Additionally, previous studies demonstrated that the increased level of Ido1 may lead to overproduction of neurotoxic metabolites and deficit of tryptophan and may contribute to inhibition of serotonin production [55,56].”
BackgroundRetractedHaarman, B. C. M., der Lek, R. F. R., Ruhé, H. G., de Groot, J. C., Nolen, W. A., & Doorduin, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_9 · Cited by 3
Perspectives for an Integrated Biomarker Approach to Drug Discovery and Development
Antonijevic, I. A., Artymyshyn, R. P., Forray, C., Rabacchi, S. A., Smith, K. E., Swanson, C. J., Tamm, J. A., Mazin, W., & Gerald, C. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_15 · Cited by 4
Depression and fatigue: Challenging comorbidities in HCV-infected patients
Hilsabeck, R. C., Webb, A., & Stern, S. L. (2007) · Current Hepatology Reports · doi:10.1007/s11901-007-0018-3 · Cited by 3
New Research in Obsessive-Compulsive Disorder and Major Depression
Aouizerate, B., & Haffen, É. (2019) · Brain Sciences · doi:10.3390/brainsci9060140 · Cited by 4
Al‐Hakeim, H. K., Abed, A. K., Moustafa, S. R., Almulla, A. F., & Maes, M. H. J. (2023) · medRxiv · doi:10.1101/2023.03.11.23287152 · Cited by 3
Self-citationA new hypothesis on preventable neuropsychiatric illness in Africa
Pollach, G., Jung, K., & Namboya, F. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.04.018 · Cited by 2
Dhawan, A., Choudhary, S., Gupta, S., Chander, A., & Dhanawat, M. (2023) · Current Drug Therapy · doi:10.2174/1574885519666230913105725 · Cited by 2
Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders
Mu, A., & Markus, J. (2011) · InTech eBooks · doi:10.5772/25532 · Cited by 1
Interferon-α, Molecular Signaling Pathways and Behavior
Wang, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-84851-8_5 · Cited by 2
Effect of Aerobic Training During Pregnancy on Seizure-Induced Depression- in Mouse
Sabaghi, A., Heyrani, A., Kiani, A., & Yousofvand, N. (2018) · The Neuroscience Journal of Shefaye Khatam · doi:10.29252/shefa.6.3.35 · Cited by 2
Mesripour, A., Gholamzadeh, E., & Yegdaneh, A. (2022) · Advanced Biomedical Research · doi:10.4103/abr.abr_186_21 · Cited by 3
“As previously mentioned IFNa can augment IDO enzyme activity that leads to an increase in kynurenine and a decrease in available tryptophan required for serotonin synthesis.[27] Interestingly the swimming behavior was increased during the active phase of the FST that is proven to be related to the serotonergic system.”
BackgroundInfluentialAarsland, T. I. M., Haavik, J., Ulvik, A., Ueland, P. M., Dols, A., & Keßler, U. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100578 · Cited by 2
Causas biológicas de depressão em doentes com lupus eritematoso sistémico: um estudo de revisão
Braga, J. C. F. F. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/v2xh-me81 · Cited by 8
Kynurenine-An Old Pathway Retraced
Shader, R. I. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000231606.45402.fd · Cited by 2
“Wichers and colleagues also treating hepatitis C patients with IFN-alpha found an association between depression symptom scores and the ratio of kynurenine to tryptophan as well as to the ratio of kynurenine to kynurenic acid.(6) The Wichers group’s article suggests that it is not a depletion of brain tryptophan that…”
BackgroundKageyama, K., Sato, M., Ito, S., Ino, Y., Nakao, S., Bunchuailua, W., Rungpragayphan, S., Krichanchai, S., Iguchi, K., Ishiguro, M., et al. (2026) · Psychiatry Research Communications · doi:10.1016/j.psycom.2026.100250 · Cited by 1
Nagata, W., & Ishizuka, T. (2026) · Human Cell · doi:10.1007/s13577-026-01381-5 · Cited by 1
[Depression and neuroplasticity. Interaction of nervous, endocrine and immune systems].
Cassano, P., & Argibay, P. F. (2010) · PubMed · Cited by 10
Walker, A. K., Dantzer, R., & Kelley, K. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4729-0_6 · Cited by 2
“[ 228 ] found that hepatitis C patients undergoing IFNa therapy experience a concurrent rise in serum kynurenine to tryptophan ratios and depressive scores.”
MethodVolpe, B. T., Mackay, M. C., Aranow, C. B., & Diamond, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00034-8 · Cited by 1
How important is psychoneuroimmunology
Leonard, B. E. (2008) · Salud Mental · Cited by 1
hsCRP in depressed outpatients. Any association to depressive symptoms?
Krogh, J., Benros, M. E., & Nordentoft, M. (2012) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2012.02.023 · Cited by 1
Metadata
- Authors
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M.
- Affiliations
- Maastricht University (NL)
- Maastricht University Medical Centre (NL)
- Ziekenhuis Oost-Limburg (BE)
- University of Antwerp (BE)
- Corresponding author
- Wichers, M C
- Venue
- Molecular Psychiatry
- Published
- 2004-10-19
- Volume
- 10
- Issue
- 6
- Pages
- 538-544
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2078660110
- Cited by
- 445
- References
- 54
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 15 · 2021: 28 · 2020: 23 · 2019: 17 · 2018: 31 · 2017: 20 · 2016: 30 · 2015: 24 · 2014: 17 · 2013: 26 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, interferon-alpha, depressive symptoms, tryptophan depletion, kynurenine pathway, kynurenic acid, neurotoxicity, chronic hepatitis C, blood-brain barrier, tryptophan availability, inflammatory cytokines
- MeSH terms
- Adult, Depression, Female, Follow-Up Studies, Humans, Immunotherapy, Kynurenic Acid, Kynurenine, Male, Middle Aged, Psychiatric Status Rating Scales, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Dioxygenases, Indoleamine-Pyrrole 2,3,-Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.